Rosa Canet-Aviles, Ph.D., is a Science Program Manager for Neuroscience at the Foundation for the National Institutes of Health (FNIH). In her role she leads a portfolio of multiple multi-year CNS disorders-related initiatives in Alzheimer’s Disease, Autism Spectrum Disorders, and Parkinson’s Disease totaling $100M+ under three public-private partnerships. Rosa manages the Biomarkers Consortium Neuroscience Steering Committee, the Accelerating Medicines Partnership (AMP) in Alzheimer’s Disease and the AMP in Parkinson’s Disease, and the Alzheimer’s disease Neuroimaging Initiative. Dr. Rosa Canet-Avilés served previously as a Science Program Officer for Neuroscience at the California Institute for Regenerative Medicine (CIRM). In her role, she planned and devised translational research programs, policies and procedures to implement and monitor the organization’s overall research and development strategy. Prior to that, Dr. Canet-Avilés served as a scientist leading some of the Neurodegeneration programs at Amgen Inc. Dr. Canet-Avilés group was responsible for the discovery and validation of therapeutic targets for Parkinson’s and Alzheimer’s Diseases.
Dr Canet-Aviles completed post-doctoral programs at the Mayo Medical school in Neuroscience, at the National Institutes on Aging (Laboratory of Neurogenetics) and a final industry post-doctoral position at Elan Inc. Dr. Canet-Avilés earned her Ph.D. degree in Neuroscience from the School of Medicine at Leeds University, UK. She also holds a BS in Organic Chemistry from the Central University of Barcelona and a Masters in Quality management from the Catalan Institute of Technology, Barcelona, Spain.